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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).SUMMARYHuman pluripotent stem cell (hPSC)-derived endothelial cells and their progenitors may provide the means for vascularization of
tissue-engineered constructs and can serve as models to study vascular development and disease. Here, we report a method to efficiently
produce endothelial cells from hPSCs via GSK3 inhibition and culture in defined media to direct hPSC differentiation to CD34+CD31+
endothelial progenitors. Exogenous vascular endothelial growth factor (VEGF) treatment was dispensable, and endothelial progenitor
differentiation was b-catenin dependent. Furthermore, by clonal analysis, we showed that CD34+CD31+CD117+TIE-2+ endothelial pro-
genitors were multipotent, capable of differentiating into calponin-expressing smooth muscle cells and CD31+CD144+vWF+I-CAM1+
endothelial cells. These endothelial cells were capable of 20 population doublings, formed tube-like structures, imported acetylated
low-density lipoprotein, and maintained a dynamic barrier function. This study provides a rapid and efficient method for production
of hPSC-derived endothelial progenitors and endothelial cells and identifies WNT/b-catenin signaling as a primary regulator for
generating vascular cells from hPSCs.INTRODUCTION
Human pluripotent stem cells (hPSCs) offer unprecedented
opportunities to study the earliest stages of human devel-
opment in vitro, to model human disease, to perform
drug tests in culture, and to develop unlimited new sources
of cells for possible therapeutic applications. To realize this
potential, it is essential to be able to control hPSC differen-
tiation to somatic lineages with high efficiency and repro-
ducibility in a scalable and inexpensive manner (Ashton
et al., 2011; Burridge et al., 2012; Kinney et al., 2014;Murry
and Keller, 2008).
Functional human endothelial cells differentiated from
hPSCs could be beneficial for many potential clinical
applications (Burridge et al., 2012; Kaupisch et al., 2012;
Levenberg et al., 2002; van derMeer et al., 2013), including
engineering new blood vessels, endothelial cell transplan-
tation into the heart for myocardial regeneration (Robey
et al., 2008), and induction of angiogenesis for treatment
of regional ischemia (Liu et al., 2014). Endothelial
cell dysfunction is also associated with many diseases,
including Alzheimer’s disease, stroke, multiple sclerosis,
and atherosclerosis (Boyle et al., 1997; Weiss et al., 2009).
hPSC-derived endothelial progenitors and endothelial cells
may provide building blocks for the establishment of
in vitro disease models for screening and development of
drugs to treat these diseases. Functionality of hPSC-derived
endothelial cells has been shown using in vitro cell culture
platforms and in vivo animal models (Adams et al., 2013;804 Stem Cell Reports j Vol. 3 j 804–816 j November 11, 2014 j ª2014 TheKusuma et al., 2013; Orlova et al., 2014; Samuel et al.,
2013; Wang et al., 2007). Similar to other somatic cells
derived from hPSCs, differentiated CD31+ endothelial cells
exhibited functional heterogeneity (Rufaihah et al., 2013).
Previously reported studies of hPSC differentiation to
endothelial cells have demonstrated that Activin/Nodal/
transforming growth factor b (TGF-b), bone morphoge-
netic protein (BMP), vascular endothelial growth factor
(VEGF), andmicroRNA-21 signaling promote this differen-
tiation (Di Bernardini et al., 2013; James et al., 2010; Kane
et al., 2010; Lu et al., 2007; Marchand et al., 2014; Rufaihah
et al., 2011; Wang et al., 2004; Zambidis et al., 2005).
In addition, mechanical sheer stress also promoted embry-
onic stem cell-derived endothelial phenotypes (Wolfe and
Ahsan, 2013).
During murine embryogenesis, hemangioblasts, which
can differentiate intomultipotent hematopoietic stem cells
and endothelial progenitors, are derived from a subpopu-
lation of mesoderm that coexpresses brachyury and KDR
(Huber et al., 2004). Similar blast colony-forming cells
were also isolated from mouse embryonic stem cell aggre-
gates in the presence of cytokines (Kennedy et al., 1997).
When cocultured with OP9 stromal cells, hPSCs differenti-
ated to mesodermal progenitors with the capacity to form
blast or hemangioblast colonies in response to fibro-
blast growth factor 2 (FGF2) (Vodyanik et al., 2010). As
another approach, hPSCs cultured as embryoid bodies
were exposed to a growth factor cocktail containing activin
A, BMP4, FGF2, and VEGF to induce differentiation toAuthors
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2013; Levenberg et al., 2002; Song et al., 2013). The
CD34+CD31+ vascular progenitor population generated
endothelial cells and smooth muscle cells in the proper
culture environments (Bai et al., 2010). TGF-b signaling
enhanced smooth muscle cell differentiation from these
endothelial progenitors, whereas the TGF-b signaling in-
hibitor SB431542 promoted endothelial cell generation
and expansion (James et al., 2010). Global gene transcrip-
tion analysis demonstrated low variability between endo-
thelial cells (ECs) differentiated from multiple lines of
human embryonic stem cells (hESCs) and induced pluripo-
tent stem cells (iPSCs) in the presence of these cytokines
(White et al., 2013). Although prior studies have demon-
strated differentiation of hPSCs to endothelial progenitors,
and subsequently to ECs and smooth muscle cells, by
applying growth factors from different signaling pathways,
it is largely unknownwhether these distinct differentiation
protocols produce identical endothelial cells and their
progenitors, and which developmental signaling mecha-
nisms are necessary and sufficient to specify these differen-
tiation fates.
Here, we describe a simple and efficient method for the
conversion of hPSCs to CD34+CD31+ endothelial progeni-
tors. Appropriate temporal activation of regulators of WNT
signaling alone, in the absence of exogenous FGF2 and
VEGF signaling, was sufficient to drive multiple hPSC lines
to differentiate to greater than 50%CD34+CD31+ endothe-
lial progenitors. However, endogenous MEK signaling was
required for hPSC differentiation to endothelial progeni-
tors because MEK inhibitor treatment substantially dimin-
ished the yield of CD34+CD31+ cells. These hPSC-derived
endothelial progenitors were further enriched to 99% pu-
rity with a single step of CD34-based magnetic separation.
Single-cell clonal differentiation assays revealed that
CD34+CD31+ endothelial progenitors generated by WNT
pathway activation were bipotent and could differentiate
to functional endothelial cells and smooth muscle cells.RESULTS
GSK3 Inhibition Is Sufficient to Induce hPSC
Differentiation to Endothelial Progenitors in the
Absence of Exogenous Growth Factors
We previously demonstrated that temporal modulation
of canonical WNT signaling is sufficient to generate
functional cardiomyocytes at high yield and purity (Lian
et al., 2012, 2013b). In that study, a virtually pure popula-
tion of brachyury+ cells was generated within 24 hr after
treatment of undifferentiated hPSCs with a GSK3 inhibitor.
In order to direct these brachyury+ cells to a cardiomyocyte
fate, we then inhibited canonical WNT signaling byStem Cell Reither expression of b-catenin small hairpin RNA (shRNA)
or treatment with small-molecule inhibitors of WNT
signaling at the proper corresponding time points. To
assess whether these GSK3 inhibitor-induced brachyury+
mesendoderm progenitors also have the potential to differ-
entiate to endothelial progenitors, we treated 19-9-11 iPSCs
with the GSK3 inhibitor CHIR99021 and subsequently
cultured the cells in StemPro-34 medium supplemented
with VEGF, both of which have been reported to stimulate
vascular cell differentiation of hPSCs (Grigoriadis et al.,
2010) (Figure 1A). After optimizing the concentrations
and timing of application of various components, the dif-
ferentiation protocol consisted of two phases. Phase I
generated brachyury+ cells by treatment of undifferenti-
ated hPSCs with CHIR990211 for 2 days, whereas phase II
directed the brachyury+ progenitors to CD34+CD31+ cells
by culture in StemPro-34 supplemented with VEGF for
3 days. We found that without CHIR99021 treatment,
very few CD34+CD31+ cells were generated from human
iPSCs, even in the presence of VEGF (Figure 1B). However,
treatment of the human iPSCs with CHIR99021 generated
more than 20% CD34+CD31+ cells. Interestingly, VEGF
treatment did not significantly increase the yield of
CD34+CD31+ cells in this differentiation system (Fig-
ure 1B). However, in the presence of sunitinib, which in-
hibits several receptor tyrosine kinases including VEGFR,
very few CD34+CD31+ cells were generated, suggesting
that endogenous VEGF signaling is required for endothelial
progenitor differentiation stimulated by CHIR99021 treat-
ment (Figure 1C). Because of these observations, we did not
include exogenous VEGF in subsequent differentiation
experiments. In addition, this differentiation protocol pri-
marily generated CD34+CD31+ cells and produced very few
CD34CD31+ or CD34+CD31 cells (Figure 1B).
We further tested the concentration dependence of
CHIR99021 for inducing CD31+CD34+ endothelial pro-
genitor differentiation and found that 6–10 mM generated
25% endothelial progenitors (Figure 1D). Similar results
were obtained in the H1 hESC line (Figure S1 available
online). These CD34+CD31+ endothelial progenitors also
expressed CD144 (VE-cadherin), but not CD45, indicating
these cells were not in hematopoietic lineages (Figure S1).
These results illustrate that induction of WNT signaling
via the GSK3 inhibitor CHIR99021 permitted subsequent
differentiation of hPSCs to CD34+CD31+ cells, and that
exogenous VEGF was not required.
Endothelial Progenitor Differentiation Induced by
GSK3 Inhibitors in hPSCs Is b-Catenin Dependent
Selectivity is a general concern with the use of chemical in-
hibitors. We tested other GSK3 inhibitors, BIO-acetoxime
and CHIR98014, and found that both also effectively
induced endothelial progenitor differentiation to a similareports j Vol. 3 j 804–816 j November 11, 2014 j ª2014 The Authors 805
Figure 1. Derivation of CD34+CD31+ Cells
from hPSCs via GSK3 Inhibitor Treatment
(A) Schematic of the protocol for differen-
tiation of hPSCs to CD34+CD31+ cells via
treatment with a GSK3 inhibitor.
(B) 19-9-11 iPSCs were cultured on Matrigel
for 2 days in LaSR basal medium with or
without 6 mM CH followed by another 3 days
in StemPro-34 medium with or without
VEGF.
(C) 19-9-11 iPSCs were cultured on Matrigel
in LaSR basal medium with 6 mM CH for
2 days followed by another 3 days in
StemPro-34 medium with 1 mM sunitinib at
indicated times.
(D) 19-9-11 iPSCs were cultured on Matrigel
in LaSR basal medium with different con-
centrations of CH for 2 days followed by
another 3 days in StemPro-34 medium. All
flow cytometric analyses of CD34 and CD31
expression were performed after 5 days of
differentiation. Data are represented as
mean ± SEM of at least three independent
replicates.
See also Figure S1.
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(Figure 2A). These small molecule compounds have
distinct chemical structures, reducing the likelihood of
shared off-target effects. However, GSK3 inhibition can
affect multiple signaling pathways, including the desired
activation of canonical WNT signaling by stabilizing b-cat-
enin protein. In order to evaluate the role of b-catenin in
GSK3 inhibitor-induced hPSC endothelial differentiation,
we generated an iPSC line (19-9-11 ishcat-1) expressing
b-catenin shRNA under the control of a tet-regulated
inducible promoter. Upon doxycycline (dox) addition,
the shRNA efficiently downregulated b-catenin expression
(Figure 2B). We used this cell line to examine the stage-spe-
cific roles of b-catenin duringmonolayer endothelial differ-
entiation stimulated by GSK3 inhibition. Undifferentiated806 Stem Cell Reports j Vol. 3 j 804–816 j November 11, 2014 j ª2014 The19-9-11 ishcat-1 iPSCs were treated with 6 mM CHIR99021
for 48 hr followed by another 3 days culture in StemPro-34
medium. Dox was added at various time points between
day 0 and day 4, and endothelial progenitor differ-
entiation was assessed at day 5 as the percentage of
CD34+CD31+cells. We found that WNT/b-catenin
signaling was essential for endothelial induction by
CHIR99021 because b-catenin knockdown at day 0 did
not generate CD34+CD31+ cells. We previously showed
that b-catenin is essential for brachyury expression after
hPSC treatment with GSK3 inhibitors (Lian et al., 2012).
We reasoned that abrogation of the CD34+CD31+ popula-
tion by b-catenin knockdown at day 0 was due to blocking
differentiation of hPSCs to brachyury-expressingmesendo-
derm progenitors. We profiled the expression of brachyuryAuthors
Figure 2. CD34+CD31+ Endothelial Pro-
genitor Differentiation Induced by GSK3
Inhibitors in hPSCs Is b-Catenin Depen-
dent
(A) 19-9-11 iPSCs were cultured on Matrigel
in LaSR basal medium containing DMSO,
0.6 mM CHIR98014, 0.6 mM BIO-acetoxime,
or 6 mM CHIR99021 for 2 days before culture
in StemPro-34 medium for 3 days. At day 5,
the percentage of CD34+CD31+ cells in cul-
ture was assessed by flow cytometry.
(B) 19-9-11 iscramble and 19-9-11 ishcat
cells were cultured in mTeSR1 containing
2 mg/ml doxycycline. After 3 days, mRNA
was collected and b-catenin expression
evaluated by qPCR. #p < 0.005, ishcat versus
iscramble; t test.
(C) 19-9-11 ishcat cells were cultured
in LaSR basal medium containing 6 mM
CHIR99021 for 2 days before exposure
to StemPro-34 medium for 3 days, with
2 mg/ml dox addition at the indicated times.
Five days after initiation of differentiation,
cells were analyzed for CD34 and CD31
expression by flow cytometry.
(D) Western blot analysis of phospho-ERK
(p-ERK) and ERK in 19-9-11 cells after 24 hr
in LaSR basal medium supplemented with
PD0325901 at the indicated concentrations.
(E) 19-9-11 cells were cultured in LaSR basal
medium containing 6 mM CHIR99021 for
2 days before exposure to StemPro-34
medium for 3 days, with 1 mM PD0325901
addition at the indicated times. Five days
after initiation of differentiation, cells were
analyzed for CD34 and CD31 expression by
flow cytometry. Data are represented as
mean ± SEM of at least three independent
replicates.
See also Figure S2.
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population of brachyury+ cells generated by day 2 in the
absence of dox. The presence of dox treatment, however,
abolished brachyury expression (Figure S2). Importantly,
depletion of b-catenin expression at time points after bra-
chyury expression was detected also reduced the percent-
age of CD34+CD31+ cells generated (Figure 2C), indicating
b-catenin might also be involved in differentiation of mes-
endoderm to CD34+CD31+ cells. Because of the important
role of FGF2 signaling on brachyury+ cell differentiation
from hPSCs (Yu et al., 2011) and the mesodermal origin
of endothelial progenitors, we used an MEK inhibitor to
study the role of MEK/ERK signaling on CD34+CD31+ cell
differentiation. We found that 1 mM of MEK inhibitor
PD0325901, which effectively blocked ERK phosphoryla-Stem Cell Rtion (Figure 2D), substantially diminished CD34+CD31+
cell differentiation, suggesting that endogenous MEK/ERK
signaling promotes endothelial progenitor differentiation
(Figure 2E).
DifferentiationMedium and Cell Density Dependence
of GSK3 Inhibitor-Induced Endothelial Progenitor
Differentiation
We have shown that hPSCs can be differentiated to
CD34+CD31+ endothelial progenitors by 2 days (phase I)
of culture in an optimized defined medium supplemented
with GSK3 inhibitors and another 3 days (phase II) in
StemPro-34 medium. In order to streamline the differenti-
ation process, we tested whether a single basal medium
could support endothelial progenitor differentiationeports j Vol. 3 j 804–816 j November 11, 2014 j ª2014 The Authors 807
Figure 3. Differentiation Medium and
Cell Density Dependence of GSK3 Inhibi-
tor-Induced Endothelial Progenitor Dif-
ferentiation
(A) Schematic of the protocol for defined,
growth factor-free differentiation of hPSCs
to endothelial progenitors in a single dif-
ferentiation medium.
(B) 19-9-11 iPSCs were cultured as indicated
in (A), with different basal differentiation
media. At day 5, cells were analyzed
for CD34 and CD31 expression by flow
cytometry. p = 0.02, LaSR basal versus
StemPro 34; t test.
(C–E) 19-9-11 iPSCs were differentiated as
described in (A) using LaSR basal medium,
with different day3 cell seeding densities.
At day 5, cells were analyzed for CD34 and
CD31 expression by flow cytometry (C). Data
are represented as mean ± SEM of at least
three independent replicates. (D) shows a
representative CD34/CD31 flow plot from a
seeding density of 0.05 million cells/cm2,
and (E) shows a representative flow cy-
tometry analysis of OCT4 expression in 19-9-
11 cells at day 0 after expansion in mTeSR
for 3 days.
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mented with CHIR99021 for 2 days (phase I) followed by
3 additional days in the same basal medium lacking exoge-
nous growth factors or chemical inhibitors (phase II). We
found that advanced DMEM/F12 supplemented with
ascorbic acid, which we termed LaSR basal medium,
was the most efficient for endothelial progenitor differ-
entiation, resulting in 25% CD34+CD31+ cells in 5 days808 Stem Cell Reports j Vol. 3 j 804–816 j November 11, 2014 j ª2014 The(Figure 3B). These results indicated the importance of basal
medium composition in endothelial progenitor differenti-
ation, with some media (e.g., RPMI/B27 and EC medium
containing serum) not supporting differentiation to any
detectable CD34+CD31+ cells (Figure 3B).
On the basis of the knowledge that initial cell density
affects hPSC differentiation fates to lineages such as cardi-
omyocytes, epithelial progenitors, and pancreatic cellsAuthors
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Differentiation of hPSCs to Endothelial Cells(Gage et al., 2013; Lian et al., 2013a; Selekman et al., 2013;
Takizawa-Shirasawa et al., 2013), we quantitatively assessed
the effect of initial cell seeding density on endothelial pro-
genitor differentiation efficiency. Singularized hPSCs were
seeded at densities ranging from 12,000 to 300,000 cells
per cm2 and then expanded in mTeSR1 for 3 days before
transition to LaSR basal medium supplemented with
CHIR99021 for 2 days and another 3 days in LaSR basalme-
dium lacking CHIR99021. The optimal seeding density was
50,000 cells per cm2 at day 3, which resulted in 325,000
cells per cm2 at day 0 (Figure 3C). At day 5, 55% of cells
seeded at this density expressed CD34 and CD31 (Figures
3C and 3D). We performed fluorescence-activated cell sort-
ing (FACS) analysis of OCT4 expression of day 0 cells and
found that more than 99.5% of the cells were OCT4+, sug-
gesting that hPSCs were pluripotent before addition of CH
(Figure 3E).
CD34+CD31+ Endothelial Progenitors AreMultipotent
Molecular analysis of endothelial progenitor differentia-
tion from hPSCs revealed dynamic changes in gene expres-
sion, with downregulation of the pluripotency markers
SOX2 and OCT4, and induction of the primitive streak-
like genes T (Nakanishi et al., 2009) and MIXL1 (Davis
et al., 2008) in the first 24 hr after CH addition (Figure 4A).
Expression of the endothelial progenitor markers CD34
and CD31 was detected at day 4 and increased at day 5
(Figure 4A). Western blot analysis of protein expression re-
vealed decreasing OCT4 expression during the first 2 days
of differentiation, and brachyury induction on days 1
and 2 followed by downregulation on day 3. The endothe-
lial marker VE-cadherin was only detected after 5 days of
differentiation (Figure 4B). Immunofluorescent analysis
revealed the expression of CD34, CD31, and VE-cadherin
on day 5 (Figure 4C). Ten days after differentiation without
passaging, however, the expression of CD34 diminished,
whereas the cells retained expression of CD31+ andVE-cad-
herin (Figure 4C).
To study the multipotent nature of the transient popula-
tion of CD34+ cells, we first enriched the day 5 differentia-
tion culture to 99% purity of CD34+ cells by magnetic-
activated cell sorting (MACS) (Figure 5A). We also enriched
the day 5 differentiation cultures of additional hESC lines
(H13, H14) and human iPSC lines (19-9-7 and 6-9-9) to
more than 99% purity of CD34+ cells (Figures S3A–S3D).
The sorted CD34+ putative endothelial progenitors were
plated on Matrigel-coated 48-well plates at a density of
one cell per well in a combinedmedium (50% smoothmus-
cle and 50% endothelial medium). After 10 days of culture,
the differentiation populations from ten different single-
cell clones contained both VE-cadherin+ von Willebrand
factor (vWF)+ cells and Calponin+ SMMHC+ (Smooth
muscle myosin heavy chain) cells, including some cells ex-Stem Cell Rpressing both endothelial and smooth muscle markers
(Figure 5B; Figures S3E and S3F), thereby demonstrating
that single CD34+ endothelial progenitors generated from
hPSCs were multipotent. In addition, when the sorted
CD34+ clones were cultured in endothelial or smoothmus-
clemedium rather than themixedmedium, they generated
relatively pure populations of endothelial cells and smooth
muscle cells, respectively (Figures 5C and 5D). The hPSC-
derived endothelial progenitors expressed C-KIT (CD117),
KDR (VEGFR2), TIE-2, CD31, CD34, CD144, but did not ex-
press vWF or intercellular adhesion molecule 1 (ICAM-1)
(Figure 6). We also quantified TIE-2, CD117, KDR, and
ICAM-1 expression with flow cytometry (Figure S4), and
results were consistent with immunostaining experiments.
The day 15 endothelial cells expressed CD31, CD144, vWF,
ICAM-1, and KDR, but did not express CD117, CD34, or
TIE-2 (Figure 6).
Characterization of Endothelial Cells Derived
from hPSCs
To study the intrinsic properties of endothelial cells differ-
entiated from hPSCs by GSK3 inhibition and culture in
LaSR basal medium, we cultivated the purified CD34+ cells
in endothelial medium on laminin-coated plates and
found that the resulting CD34+CD31+vWF+CD144+ endo-
thelial cells were capable of approximately 20 population
doublings over 2 months, generating more than 1 million
cells from a single endothelial cell (Figure 7A). After
2 months in culture, the cells still expressed CD31 and
VE-cadherin based on immunostaining (Figure 7B). Flow
cytometry analysis also showed that more than 99% of
cells expressed CD31 and VE-cadherin after 60 days in cul-
ture (Figure S5). Furthermore, upon treatment with exoge-
nous VEGF, the CD144+ cells formed vascular tubes in
Matrigel matrix (Figure 7C) and were capable of acetylated
low-density lipoprotein (AcLDL) uptake, indicative of
endothelial function (Figure 7D). The endothelium also re-
sponds to inflammatory mediators, such as tumor necrosis
factor a (TNF-a), by upregulating adhesion molecules
including ICAM-1, which has been implicated in the cap-
ture of circulating leukocytes. Although unstimulated
endothelial cells expressed low levels of ICAM-1, TNF-a
treatment greatly increased the expression of ICAM-1 in
the hPSC-derived endothelial cells (Figure 7E).
To characterize the barrier phenotype of the hPSC-
derived endothelial cells, we measured the transendothe-
lial electrical resistance (TEER) and transport of fluorescent
40 kDa dextran across a monolayer of differentiated endo-
thelial cells. VEGF treatment induced a sustained decrease
in TEER and an increase in dextran permeability. However,
treatment of endothelial cells with the cAMP analog
8-pCPT-20O-Me-cAMP (o-Me) decreased dextran perme-
ability and increased TEER (Figures 7F and 7G).eports j Vol. 3 j 804–816 j November 11, 2014 j ª2014 The Authors 809
Figure 4. Molecular Analysis of Endothelial Progenitors Differentiated from hPSCs
19-9-11 iPSCs were differentiated as illustrated in Figure 3A using LaSR basal medium. At different time points, developmental gene or
protein expression was assessed by quantitative RT-PCR (A) or western blot (B). Data are represented as mean ± SEM of at least three
independent replicates. At 5 days or 10 days postdifferentiation, immunostaining for CD34, CD31, and VE-cadherin was performed (C).
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Prior reports of differentiating hPSCs to endothelial cells
required the addition of expensive growth factors and/or810 Stem Cell Reports j Vol. 3 j 804–816 j November 11, 2014 j ª2014 Theundefined serum to direct endothelial development, and
thesemethods generated heterogeneous cell mixtures typi-
cally containing less than 10% endothelial cells. Here, we
show that small-molecule activation of canonical WNTAuthors
Figure 5. CD34+CD31+ Endothelial Pro-
genitors Are Multipotent
19-9-11 iPSCs were differentiated as
illustrated in Figure 3A using LaSR basal
medium.
(A) At day 5, CD34+ cells were enriched
with the EasySep Human CD34 Positive
Selection Kit and purification quantified by
flow cytometry for CD34 expression.
(B–D) Sorted CD34+ cells were cultured in
a combined medium (B), a smooth muscle
medium (C), or an endothelial medium (D)
at a density of one cell per well in a 48-well
plate for another 10 days. Sample immuno-
fluorescence images for smooth muscle
and endothelial markers were shown. In (B),
arrows point to SMMHC+VE-cadherin cells.
See also Figure S3.
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growth factors, is sufficient to generate high yields of
CD34+CD31+ endothelial progenitors from hPSCs. Prior
to this study, endothelial progenitors have not been
isolated from hPSCs under defined conditions, and the
mechanisms by which developmental signaling pathways
regulate endothelial progenitor commitment remained
largely unknown (Slukvin, 2013). With a doxycyline-
inducible shRNA knockdown of the WNT pathway modu-
lator b-catenin, we identified that b-catenin is required
for CD34+CD31+ endothelial progenitor generation from
hPSCs following GSK3 inhibition. Furthermore, although
previous reports required more than 10 days to generate
CD34+CD31+ cells, this small molecule differentiation
approach accelerates developmental timing and converts
hPSCs to greater than 50% CD34+CD31+ cells in 19-9-11
iPSCs in 5 days. This protocol produced more than 99%
pure populations of CD34+CD31+ cells from six different
hPSC lines following a single magnetic affinity separation.
GSK3 inhibition has been shown to be a potent inducer of
mesendoderm lineage commitment in hPSCs (Tan et al.,
2013). The WNT pathway exhibits crosstalk with a variety
of other developmental signaling networks, includingStem Cell RTGF-b superfamily (Cai et al., 2013), FGF (Stulberg et al.,
2012), Notch (Wang et al., 2013), Hippo (Hergovich and
Hemmings, 2010), and retinoic acid signaling (Chanda
et al., 2013). The necessity of b-catenin in generating
CD34+CD31+ cells indicates a direct role of canonical WNT
signaling in endothelial progenitor differentiation, whereas
thediminishedyield ofCD34+CD31+ cells in thepresenceof
MEKand receptor tyrosine kinase inhibitors suggests endog-
enous pathways also mediate endothelial progenitor differ-
entiation. Thus, canonical WNT signaling is not the only
pathway required for endothelial progenitor specification,
but it may act as a master regulator to orchestrate signaling
that leads to endothelial progenitor differentiation.
We have previously reported a method to differentiate
hPSCs to a relatively pure population of cardiomyocytes
by dynamic modulation of canonical WNT signaling using
small-molecule GSK3 inhibitors and Porcupine inhibitors
in a RPMI/B27 medium lacking insulin (Lian et al., 2012,
2013a). This protocol uses WNT pathway activation to
direct mesendoderm differentiation, followed by WNT
pathway inhibition to specify cardiac mesoderm and cardi-
omyocyte fates. Although the small molecule cardiomyo-
cyte and endothelial progenitor differentiation protocolseports j Vol. 3 j 804–816 j November 11, 2014 j ª2014 The Authors 811
Figure 6. Day 5 Endothelial Progenitors Differ from Day 15 Endothelial Cells in Marker Expression
19-9-11 iPSCs were differentiated as illustrated in Figure 3A using LaSR basal medium, and unsorted day 5 progenitor cells and day 15
endothelial cells were immunostained for developmental markers as indicated. See also Figure S4.
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both progress through mesodermal progenitors via GSK3
inhibition. These mesodermal progenitors can be directed
to spontaneously contracting cardiomyocytes via WNT in-
hibition, while permitting endogenous canonical WNT
signaling yields a population enriched in endothelial pro-
genitors. Together, these results demonstrate the concept
of chemically guiding differentiation to distinct cell types
via different patterns of modulation of master regulators
of cell fates. This paradigmmay represent a promising gen-
eral approach to efficiently produce cells and tissues from
stem cell sources in a defined manner.
Interestingly, the WNT pathway-induced endothelial
progenitor differentiation protocol primarily generates
CD34 and CD31 double-positive cells, as opposed to
other methods using BMP4, which produce a mixture
of CD34+CD31, CD34+CD31+, CD34CD31+ cells (Bai
et al., 2010; Song et al., 2013). The CD34+CD31+ endothe-
lial progenitors may be more amenable to large-scale
expansion. Furthermore, these endothelial progenitors
can be further directed to endothelial cells or smooth812 Stem Cell Reports j Vol. 3 j 804–816 j November 11, 2014 j ª2014 Themuscle cells by culture in the appropriate inductive
media. Purified CD31+VE-cadherin+vWF+CD34 endothe-
lial cells were expanded for 20 doublings over 2 months
and maintained expression of endothelial cell markers
(CD31+VE-cadherin+CD34). These cells exhibited uptake
of acetylated low-density lipoprotein and formed tube-
like structures when cultured on Matrigel. These endothe-
lial cells also responded to TNF-a treatment by increasing
ICAM-1 expression and maintained a dynamic barrier,
responding to VEGF and cAMP analog by increasing or
decreasing dextran permeability, respectively. Our findings
demonstrate efficient and reproducible endothelial pro-
genitor and endothelial differentiation of hPSCs by GSK3
inhibition in the absence of exogenous growth factor
stimulation.EXPERIMENTAL PROCEDURES
Maintenance of hPSCs
Transgene and vector free human iPSCs (19-9-11, 19-9-7, 6-9-9) (Yu
et al., 2009) and hESCs (H1, H13, H14) (Thomson et al., 1998) wereAuthors
Figure 7. Characterization of Endothelial
Cells Derived from hPSCs
(A) 19-9-11 iPSCs were differentiated as
illustrated in Figure 3A using LaSR basal
medium. At day 5, CD34+ cells were enriched
and cultured in endothelial medium on
laminin-coated plates. At different time
points, the cell numbers were counted.
(B–D) The purified day 60 endothelial cells
were immunostained with VE-cadherin and
CD31 (B) and tested for tube-forming ability
upon VEGF treatment (C) and the ability to
uptake AcLDL (D).
(E) Flow cytometry analysis of surface
protein expression of ICAM-1 of untreated
cells or cells treated with 10 ng/ml TNF-a for
16 hr.
(F and G) Barrier phenotype of the hPSC-
derived endothelial cells. Endothelial cells
were differentiated as illustrated in Fig-
ure 3A using LaSR basal medium and then
CD34+ cells were enriched by MACS and
cultured on laminin in endothelial cell
medium. After 10 days in culture, the
endothelial cells were seeded on collagen/
fibronectin coated transwell filters and
maintained in endothelial SFM. Barrier
function was assessed by measuring TEER
48 hr after seeding. Next, cells were treated
with endothelial SFM containing 100 ng/ml
VEGF or 10 mM oME. In (F), TEER was
measured as a function of time, and
normalized to the initial TEER value (36.7 ±
4.3 Ucm2. In (G), TEER and fluorescent
dextran permeability were measured 24 hr
after plating. **p < 0.005, VEGF (or oME)
versus control; t test.
Data are represented as mean ± SEM of at
least three independent replicates. See also
Figure S5.
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in mTeSR1 medium (STEMCELL Technologies) according to a pre-
viously published method (Lian et al., 2013a).
Endothelial Progenitor Differentiation via
Modulation of Canonical WNT Signaling
hPSCs maintained on a Matrigel-coated surface in mTeSR1 were
dissociated into single cells with Accutase (Life Technologies) at
37C for 5min and then seeded onto aMatrigel-coated cell culture
dish at 50,000 cell/cm2 inmTeSR1 supplemented with 5 mMROCK
inhibitor Y-27632 (Selleckchem) (day3) for 24 hr. Cells were then
cultured inmTeSR1, changed daily. At day 0, cells were treatedwith
6–10 mM CHIR99021 (Selleckchem) for 2 days in LaSR basal me-
dium,whichconsistsofAdvancedDMEM/F12, 2.5mMGlutaMAX,
and 60 mg/ml ascorbic acid (Sigma, A8960). After 2 days,
CHIR99021-containingmediumwasaspirated andcellsweremain-Stem Cell Rtained in LaSR basal medium without CHIR99021 for 3–4 addi-
tional days. PD0325901 was purchased from Tocris Bioscience.
Differentiation of CD34+ Cells to Endothelial Cells
Day 5 differentiated populations were dissociated with Accutase
for 10 min and purified with an EasySep Magnet kit (STEMCELL
Technologies) using a CD34 antibody according to the manufac-
turer’s instructions. The purified CD34+ cells were plated on
collagen-IV-coated dishes (BD BioCoat) in EGM-2medium (Lonza)
and split every 4–5 days with Accutase.
Differentiation of CD34+ Cells to Smooth Muscle Cells
Day 5 differentiated populations were dissociated with Accutase
for 10 min and purified with an EasySep Magnet kit (STEMCELL
Technologies) using a CD34 antibody according to the manu-
facturer’s instructions. The purified CD34+ cells were plated oneports j Vol. 3 j 804–816 j November 11, 2014 j ª2014 The Authors 813
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(Lonza) and split every 4–5 days with Accutase.
Vascular Tube Formation Assay
To assess the formation of capillary structures, 13 105 endothelial
cells in 0.4 ml EGM-2 medium (Lonza) supplemented with
50 ng/ml VEGF (R&D Systems) were plated into one well of 24-
well tissue culture plate precoated with 250 ml Matrigel (BD Biosci-
ence). Tube formationwas observed by lightmicroscopy after 24 hr
of incubation.
RT-PCR and Quantitative RT-PCR
Total RNA was prepared with the RNeasy mini kit (QIAGEN) and
treated with DNase (QIAGEN). One microgram RNA was reverse
transcribed into cDNA via Oligo (dT) with Superscript III Reverse
Transcriptase (Invitrogen). Real-time quantitative PCR was done
in triplicate with iQSYBR Green SuperMix (Bio-Rad). RT-PCR was
performed with Gotaq Master Mix (Promega) and then subjected
to 2% agarose gel electrophoresis. ACTB was used as an endoge-
nous housekeeping control. PCR primer sequences are provided
in the Supplemental Experimental Procedures.
Flow Cytometry
Cellswere dissociated into single cellswithAccutase for 10min and
then fixed with 1% paraformaldehyde for 20 min at room temper-
ature and stained with primary and secondary antibodies (Supple-
mental Experimental Procedures) in PBS plus 0.1% Triton X-100
and 0.5% BSA. Data were collected on a FACSCaliber flow cytome-
ter (Beckton Dickinson) and analyzed using FlowJo. FACS gating
was based on the corresponding isotype antibody control.
Immunostaining
Cells were fixed with 4% paraformaldehyde for 15 min at room
temperature and then stained with primary and secondary anti-
bodies (Supplemental Experimental Procedures) in PBS plus 0.4%
Triton X-100 and 5% nonfat dry milk (Bio-Rad). Nuclei were
stained with Gold antifade Reagent with DAPI (Invitrogen).
An epifluorescence microscope (Leica DM IRB) with a QImaging
Retiga 4000R camera was used for imaging analysis.
Western Blot Analysis
Cells were lysed in M-PER Mammalian Protein Extraction Reagent
(Pierce) in the presence of Halt Protease and Phosphatase Inhibitor
Cocktail (Pierce). Proteinswere separated by 10%Tris-Glycine SDS/
PAGE (Invitrogen) under denaturing conditions and transferred to
a nitrocellulose membrane. After blocking with 5% dried milk in
TBST, the membrane was incubated with primary antibody over-
night at 4C. The membrane was then washed, incubated with
an anti-mouse/rabbit peroxidase-conjugated secondary antibody
(Supplemental Experimental Procedures) at room temperature for
1 hr, and developed by SuperSignal chemiluminescence (Pierce).
Monolayer Integrity
Purified CD31+ endothelial cells were seeded on 12-well plate
size 0.4 mm porous polystyrene membrane inserts (Transwells,
Corning) coatedwith a 0.4mg/ml collagen IVand 0.1mg/ml fibro-814 Stem Cell Reports j Vol. 3 j 804–816 j November 11, 2014 j ª2014 Thenectin mixture at a density of 250,000 cells/insert. Cells were
maintained in endothelial cell serum-free medium (SFM) (Life
Technologies) for 48 hr prior to addition 0.5ml and 1.5ml of endo-
thelial SFMat the apical and basolateral chambers respectively. Bar-
rier tightness was assessed by measurement of transendothelial
electrical resistance (TEER) using aEVOM STX2 electrode system
(World Precision Instruments) before medium replacement. Base-
line resistance values served to normalize subsequent TEER mea-
surements. Cells were treated with either 100 ng/ml vascular
endothelial growth factor (VEGF) or 10 mM 8-(4-chlorophe-
nylthio)-20-O-Me-cAMP (oMe). TEERmeasurements were acquired
every 2 hr, with the exception of oME-treated cells. After 24 hr of
treatment, vascular permeability was assessed by replacing the
medium in the top chamber with 500 ml of 1 mM40 kDa fluorescein
isothiocyanate-dextran (Sigma-Aldrich) dissolved in endothelium
SFM. At 15, 30, 45, and 60 min, 150 ml aliquots were taken from
the basolateral chamber and replaced with warm endothelial
SFM. Cell permeability was calculated following the Pe clearance
method (Calabria et al., 2006; Jones and Shusta, 2007).
Statistics
Data are presented as mean ± SEM. Statistical significance
was determined by Student’s t test (two-tail) between two groups.
p < 0.05 was considered statistically significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures and five figures and can be found with this article
online at http://dx.doi.org/10.1016/j.stemcr.2014.09.005.
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